We have confidence in our ability to support our Sponsors and sites in meeting clinical trial goals – because we’ve done it before. Our experienced team has successfully enrolled even the most challenging clinical trials across therapeutic areas.
Stephen DeCherney, MD, MPH is currently a Professor of Medicine (Endocrinology and Metabolism) and former Professor of Business at the University of North Carolina. He is an Operating Partner at Grant Avenue Capital (NY). He serves on the Boards of KNOW Bio LLC, Vast Therapeutics Inc, and Pharm-Olam CRO. He is an Executive Advisor to Anagenesis Capital Partners (West Palm, FL) and e4-Services (Philadelphia PA).
He was formerly President, Quintiles (now IQVIA) Global CRO.
He serves on the Board of the RFK Center for Human Rights. He is a Trustee of the William Harvey Research Institute of Queen Mary University London; The University of Delaware Research Foundation; and The Christiana Care Health System (Delaware).
Dr. DeCherney is a graduate of Columbia College of Columbia University, Columbia University School of Public Health (Healthcare Policy and Management), and Temple University School of Medicine.
E.B. is an entrepreneur experienced in executive management, startup & turn-around situations, clinical development, business development, strategic planning/development, and enabling technologies in various industries. Prior to starting Helios, E.B. was a Senior Vice President at ICON plc and drove the development of their site and patient strategy – including ICON’s global clinical research site network, its home health provider (home nursing), global patient recruitment and retention services, and developing operating solutions to deliver decentralized clinical trials (DCTs). He is the author of many white papers focused on patient engagement and site support, as well as DCT technologies deployment.
Prior to joining ICON, E.B. was a co-founder of Accelovance, a US-based clinical research site network. The company was recognized at the 2009, 2010, and 2011 World Vaccine Congress as the Best Vaccine Clinical Research Organization.
Natalie brings over 20 years of corporate leadership in both private and public companies. Most recently she served as Chief Financial Officer of Allucent where she led many operational and financial areas of the business including global transactions and operational expansion. Prior roles include Chief Financial Officer of ApoCell, Inc., a molecular biomarker company, and roles with progressing responsibility in several industries including banking, manufacturing, technology, and service businesses.
Sergio has a history of successful sales leadership in the clinical research industry. Prior to joining Helios, he was Vice President, Business Development for the Review Services division of Advarra where Sergio had responsibility for managing business development supporting the company’s Large Pharma and CRO customer base as well as supporting marketing and building out the business development functionality for our group. Additionally, he held senior level business development positions at Greenphire where he helped launch the patient payment business and Bio-Optronics where he helped launch the Clinical Conductor Enterprise offering.
Sergio is Treasurer and Member, Board of Trustees of ACRP. He is also an avid cyclist and created the ACRP R4DE! (Ride for Diversity, Equity, and Inclusion) a 360-mile self-supported bicycle ride to raise awareness and support ACRP’s efforts in the area of diversity and inclusion in the clinical research workforce.